AAAAAA

   
Results: 1-10 |
Results: 10
Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject
Authors: Mohr, DC Boudewyn, AC Likosky, W Levine, E Goodkin, DE
Citation: Dc. Mohr et al., Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject, ANN BEHAV M, 23(2), 2001, pp. 125-132
Multiple sclerosis: Empirical literature for the clinical health psychologist
Authors: Mohr, DC Cox, D
Citation: Dc. Mohr et D. Cox, Multiple sclerosis: Empirical literature for the clinical health psychologist, J CLIN PSYC, 57(4), 2001, pp. 479-499
Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis
Authors: Mohr, DC Goodkin, DE Islar, J Hauser, SL Genain, CP
Citation: Dc. Mohr et al., Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis, ARCH NEUROL, 58(7), 2001, pp. 1081-1086
Psychological stress and the subsequent appearance of new brain MRI lesions in MS
Authors: Mohr, DC Goodkin, DE Bacchetti, P Boudewyn, AC Huang, L Marrietta, P Cheuk, W Dee, B
Citation: Dc. Mohr et al., Psychological stress and the subsequent appearance of new brain MRI lesions in MS, NEUROLOGY, 55(1), 2000, pp. 55-61
Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis
Authors: Mohr, DC Likosky, W Bertagnolli, A Goodkin, DE Van der Wende, J Dwyer, P Dick, LP
Citation: Dc. Mohr et al., Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis, J CONS CLIN, 68(2), 2000, pp. 356-361
Treatment adherence and patient retention in the first year of a Phase-IIIclinical trial for the treatment of multiple sclerosis
Authors: Mohr, DC Goodkin, DE Masuoka, L Dick, LP Russo, D Eckhardt, J Boudewyn, AC Bedell, L
Citation: Dc. Mohr et al., Treatment adherence and patient retention in the first year of a Phase-IIIclinical trial for the treatment of multiple sclerosis, MULT SCLER, 5(3), 1999, pp. 192-197
Treatment of depression in multiple sclerosis: Review and meta-analysis
Authors: Mohr, DC Goodkin, DE
Citation: Dc. Mohr et De. Goodkin, Treatment of depression in multiple sclerosis: Review and meta-analysis, CL PSYCH-SC, 6(1), 1999, pp. 1-9
The psychosocial impact of multiple sclerosis: Exploring the patient's perspective
Authors: Mohr, DC Dick, LP Russo, D Likosky, W Pinn, J Boudewyn, AC Goodkin, DE
Citation: Dc. Mohr et al., The psychosocial impact of multiple sclerosis: Exploring the patient's perspective, HEALTH PSYC, 18(4), 1999, pp. 376-382
Course of depression during the initiation of interferon beta-1a treatmentfor multiple sclerosis
Authors: Mohr, DC Likosky, W Dwyer, P Van der Wende, J Boudewyn, AC Goodkin, DE
Citation: Dc. Mohr et al., Course of depression during the initiation of interferon beta-1a treatmentfor multiple sclerosis, ARCH NEUROL, 56(10), 1999, pp. 1263-1265
Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a
Authors: Mohr, DC Likosky, W Boudewyn, AC Marietta, P Dwyer, P Van Der Wende, J Goodkin, DE
Citation: Dc. Mohr et al., Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a, MULT SCLER, 4(6), 1998, pp. 487-489
Risultati: 1-10 |